Literature DB >> 2862099

Treatment of relapsing bleeding peptic ulcers with the somatostatin analogue SMS 201 995 in a patient with Zollinger-Ellison syndrome.

B Wörmann, K Kutz, R Ottenjann.   

Abstract

SMS 201-995 is an octapeptide analogue of natural somatostatin characterized by pharmacological properties similar to those of somatostatin itself. In addition, its serum half-life of about 60 minutes after i.v. injection is significantly longer than that of the natural compound. A patient with active bleeding from a peptic ulcer jejuni due to a Zollinger-Ellison syndrome was successfully treated with SMS 201-995. Bleeding stopped after continuous infusion (25 micrograms/h) within the first 24 hours of infusion. The serum gastrin concentration dropped from 3,300 pg/ml to 170 pg/ ml (normal range 40-100 pg/ml). Continuation of the treatment by subcutaneous injections of SMS 201-995 (100 micrograms twice daily) maintained serum gastrin concentrations between 300 to 400 pg/ml over a period of 8 months. Side effects have not been observed. Four subsequent endoscopic examinations have revealed no ulcer relapse.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2862099

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  3 in total

1.  Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study.

Authors:  Sara Massironi; Federica Cavalcoli; Alessandra Elvevi; Maurizio Quatrini; Pietro Invernizzi
Journal:  Endocrine       Date:  2021-10-29       Impact factor: 3.633

Review 2.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 3.  The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?

Authors:  Valentina Guarnotta; Chiara Martini; Maria Vittoria Davì; Genoveffa Pizza; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2017-10-10       Impact factor: 3.633

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.